ProShares Ultra NASDAQ Biotechnology
BIB
BIB
24 hedge funds and large institutions have $3.62M invested in ProShares Ultra NASDAQ Biotechnology in 2024 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 4 increasing their positions, 5 reducing their positions, and 4 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more call options, than puts
Call options by funds: $ | Put options by funds: $
more funds holding
Funds holding: →
less ownership
Funds ownership: →
20% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 5
44% less capital invested
Capital invested by funds: $6.5M → $3.62M (-$2.88M)
Holders
24
Holding in Top 10
–
Calls
$537K
Puts
$436K
Top Buyers
| 1 | +$197K | |
| 2 | +$64.1K | |
| 3 | +$29.8K | |
| 4 |
LWANC
Laurel Wealth Advisors (North Carolina)
Charlotte,
North Carolina
|
+$15.2K |
| 5 |
MCM
MAI Capital Management
Independence,
Ohio
|
+$12.7K |
Top Sellers
| 1 | -$1.46M | |
| 2 | -$306K | |
| 3 | -$304K | |
| 4 |
TFA
Toth Financial Advisory
Leesburg,
Virginia
|
-$142K |
| 5 |
Morgan Stanley
New York
|
-$31K |